Detailed account on activation mechanisms of ruthenium coordination complexes and their role as antineoplastic agents
Ruthenium (Ru) complexes are known for their promising anticancer activity presumably due to octahedral coordination geometry, slow ligand exchange rate, the range of different oxidation states and target specificity. This review article summarizes the physicochemical processes which are responsible...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Pal, Mousumi [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2018transfer abstract |
|---|
| Schlagwörter: |
Ruthenium-glutathione-S-transferase inhibitors |
|---|
| Umfang: |
27 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles - Jose, Ajay ELSEVIER, 2018, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:150 ; year:2018 ; day:25 ; month:04 ; pages:419-445 ; extent:27 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ejmech.2018.03.015 |
|---|
| Katalog-ID: |
ELV042585953 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV042585953 | ||
| 003 | DE-627 | ||
| 005 | 20230626001819.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180726s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejmech.2018.03.015 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000550.pica |
| 035 | |a (DE-627)ELV042585953 | ||
| 035 | |a (ELSEVIER)S0223-5234(18)30250-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |a 540 |q VZ |
| 084 | |a BIODIV |q DE-30 |2 fid | ||
| 084 | |a 42.00 |2 bkl | ||
| 100 | 1 | |a Pal, Mousumi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Detailed account on activation mechanisms of ruthenium coordination complexes and their role as antineoplastic agents |
| 264 | 1 | |c 2018transfer abstract | |
| 300 | |a 27 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Ruthenium (Ru) complexes are known for their promising anticancer activity presumably due to octahedral coordination geometry, slow ligand exchange rate, the range of different oxidation states and target specificity. This review article summarizes the physicochemical processes which are responsible for the selectivity of Ru complexes toward cancer cells over the normal cells. Emphasis has been given on the activation mechanism of Ru(III) complex administered as a prodrug and then the release of active species in an acidic environment of cancer cell through normal or photo induced hydrolysis or ligand oxidation. This article also elaborates how active Ru complex can be designed by their rate of hydrolysis, kinetics of ligand exchange, pKa of the aquated species. The article further articulates how Ru complexes inhibit tumor growth via multiple events such as transferrin/albumin binding, ROS generation, inhibition of glutathione-S-transferases and kinases and DNA intercalation. Based on the above understanding, examples of various Ru complexes with their in-vitro cell based cytotoxicity and mechanism of action have been described to make this review comprehensive for future Ru based anticancer drug development. In the end, comments have been made on some emerging concepts regarding lack of innertness of Ru(III) complexes vis-à-vis Ru(II) species. | ||
| 520 | |a Ruthenium (Ru) complexes are known for their promising anticancer activity presumably due to octahedral coordination geometry, slow ligand exchange rate, the range of different oxidation states and target specificity. This review article summarizes the physicochemical processes which are responsible for the selectivity of Ru complexes toward cancer cells over the normal cells. Emphasis has been given on the activation mechanism of Ru(III) complex administered as a prodrug and then the release of active species in an acidic environment of cancer cell through normal or photo induced hydrolysis or ligand oxidation. This article also elaborates how active Ru complex can be designed by their rate of hydrolysis, kinetics of ligand exchange, pKa of the aquated species. The article further articulates how Ru complexes inhibit tumor growth via multiple events such as transferrin/albumin binding, ROS generation, inhibition of glutathione-S-transferases and kinases and DNA intercalation. Based on the above understanding, examples of various Ru complexes with their in-vitro cell based cytotoxicity and mechanism of action have been described to make this review comprehensive for future Ru based anticancer drug development. In the end, comments have been made on some emerging concepts regarding lack of innertness of Ru(III) complexes vis-à-vis Ru(II) species. | ||
| 650 | 7 | |a Ligand exchange rate |2 Elsevier | |
| 650 | 7 | |a Ruthenium-glutathione-S-transferase inhibitors |2 Elsevier | |
| 650 | 7 | |a DNA damage |2 Elsevier | |
| 650 | 7 | |a Anticancer |2 Elsevier | |
| 650 | 7 | |a Ruthenium-coordination complex |2 Elsevier | |
| 650 | 7 | |a Kinase inhibitor |2 Elsevier | |
| 700 | 1 | |a Nandi, Utpal |4 oth | |
| 700 | 1 | |a Mukherjee, Debaraj |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Jose, Ajay ELSEVIER |t Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles |d 2018 |g Amsterdam [u.a.] |w (DE-627)ELV000457477 |
| 773 | 1 | 8 | |g volume:150 |g year:2018 |g day:25 |g month:04 |g pages:419-445 |g extent:27 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejmech.2018.03.015 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a FID-BIODIV | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 42.00 |j Biologie: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 150 |j 2018 |b 25 |c 0425 |h 419-445 |g 27 | ||
| author_variant |
m p mp |
|---|---|
| matchkey_str |
palmousuminandiutpalmukherjeedebaraj:2018----:ealdconoatvtomcaimorteimoriainopeeadh |
| hierarchy_sort_str |
2018transfer abstract |
| bklnumber |
42.00 |
| publishDate |
2018 |
| allfields |
10.1016/j.ejmech.2018.03.015 doi GBV00000000000550.pica (DE-627)ELV042585953 (ELSEVIER)S0223-5234(18)30250-2 DE-627 ger DE-627 rakwb eng 570 540 VZ BIODIV DE-30 fid 42.00 bkl Pal, Mousumi verfasserin aut Detailed account on activation mechanisms of ruthenium coordination complexes and their role as antineoplastic agents 2018transfer abstract 27 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Ruthenium (Ru) complexes are known for their promising anticancer activity presumably due to octahedral coordination geometry, slow ligand exchange rate, the range of different oxidation states and target specificity. This review article summarizes the physicochemical processes which are responsible for the selectivity of Ru complexes toward cancer cells over the normal cells. Emphasis has been given on the activation mechanism of Ru(III) complex administered as a prodrug and then the release of active species in an acidic environment of cancer cell through normal or photo induced hydrolysis or ligand oxidation. This article also elaborates how active Ru complex can be designed by their rate of hydrolysis, kinetics of ligand exchange, pKa of the aquated species. The article further articulates how Ru complexes inhibit tumor growth via multiple events such as transferrin/albumin binding, ROS generation, inhibition of glutathione-S-transferases and kinases and DNA intercalation. Based on the above understanding, examples of various Ru complexes with their in-vitro cell based cytotoxicity and mechanism of action have been described to make this review comprehensive for future Ru based anticancer drug development. In the end, comments have been made on some emerging concepts regarding lack of innertness of Ru(III) complexes vis-à-vis Ru(II) species. Ruthenium (Ru) complexes are known for their promising anticancer activity presumably due to octahedral coordination geometry, slow ligand exchange rate, the range of different oxidation states and target specificity. This review article summarizes the physicochemical processes which are responsible for the selectivity of Ru complexes toward cancer cells over the normal cells. Emphasis has been given on the activation mechanism of Ru(III) complex administered as a prodrug and then the release of active species in an acidic environment of cancer cell through normal or photo induced hydrolysis or ligand oxidation. This article also elaborates how active Ru complex can be designed by their rate of hydrolysis, kinetics of ligand exchange, pKa of the aquated species. The article further articulates how Ru complexes inhibit tumor growth via multiple events such as transferrin/albumin binding, ROS generation, inhibition of glutathione-S-transferases and kinases and DNA intercalation. Based on the above understanding, examples of various Ru complexes with their in-vitro cell based cytotoxicity and mechanism of action have been described to make this review comprehensive for future Ru based anticancer drug development. In the end, comments have been made on some emerging concepts regarding lack of innertness of Ru(III) complexes vis-à-vis Ru(II) species. Ligand exchange rate Elsevier Ruthenium-glutathione-S-transferase inhibitors Elsevier DNA damage Elsevier Anticancer Elsevier Ruthenium-coordination complex Elsevier Kinase inhibitor Elsevier Nandi, Utpal oth Mukherjee, Debaraj oth Enthalten in Elsevier Science Jose, Ajay ELSEVIER Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles 2018 Amsterdam [u.a.] (DE-627)ELV000457477 volume:150 year:2018 day:25 month:04 pages:419-445 extent:27 https://doi.org/10.1016/j.ejmech.2018.03.015 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 42.00 Biologie: Allgemeines VZ AR 150 2018 25 0425 419-445 27 |
| spelling |
10.1016/j.ejmech.2018.03.015 doi GBV00000000000550.pica (DE-627)ELV042585953 (ELSEVIER)S0223-5234(18)30250-2 DE-627 ger DE-627 rakwb eng 570 540 VZ BIODIV DE-30 fid 42.00 bkl Pal, Mousumi verfasserin aut Detailed account on activation mechanisms of ruthenium coordination complexes and their role as antineoplastic agents 2018transfer abstract 27 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Ruthenium (Ru) complexes are known for their promising anticancer activity presumably due to octahedral coordination geometry, slow ligand exchange rate, the range of different oxidation states and target specificity. This review article summarizes the physicochemical processes which are responsible for the selectivity of Ru complexes toward cancer cells over the normal cells. Emphasis has been given on the activation mechanism of Ru(III) complex administered as a prodrug and then the release of active species in an acidic environment of cancer cell through normal or photo induced hydrolysis or ligand oxidation. This article also elaborates how active Ru complex can be designed by their rate of hydrolysis, kinetics of ligand exchange, pKa of the aquated species. The article further articulates how Ru complexes inhibit tumor growth via multiple events such as transferrin/albumin binding, ROS generation, inhibition of glutathione-S-transferases and kinases and DNA intercalation. Based on the above understanding, examples of various Ru complexes with their in-vitro cell based cytotoxicity and mechanism of action have been described to make this review comprehensive for future Ru based anticancer drug development. In the end, comments have been made on some emerging concepts regarding lack of innertness of Ru(III) complexes vis-à-vis Ru(II) species. Ruthenium (Ru) complexes are known for their promising anticancer activity presumably due to octahedral coordination geometry, slow ligand exchange rate, the range of different oxidation states and target specificity. This review article summarizes the physicochemical processes which are responsible for the selectivity of Ru complexes toward cancer cells over the normal cells. Emphasis has been given on the activation mechanism of Ru(III) complex administered as a prodrug and then the release of active species in an acidic environment of cancer cell through normal or photo induced hydrolysis or ligand oxidation. This article also elaborates how active Ru complex can be designed by their rate of hydrolysis, kinetics of ligand exchange, pKa of the aquated species. The article further articulates how Ru complexes inhibit tumor growth via multiple events such as transferrin/albumin binding, ROS generation, inhibition of glutathione-S-transferases and kinases and DNA intercalation. Based on the above understanding, examples of various Ru complexes with their in-vitro cell based cytotoxicity and mechanism of action have been described to make this review comprehensive for future Ru based anticancer drug development. In the end, comments have been made on some emerging concepts regarding lack of innertness of Ru(III) complexes vis-à-vis Ru(II) species. Ligand exchange rate Elsevier Ruthenium-glutathione-S-transferase inhibitors Elsevier DNA damage Elsevier Anticancer Elsevier Ruthenium-coordination complex Elsevier Kinase inhibitor Elsevier Nandi, Utpal oth Mukherjee, Debaraj oth Enthalten in Elsevier Science Jose, Ajay ELSEVIER Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles 2018 Amsterdam [u.a.] (DE-627)ELV000457477 volume:150 year:2018 day:25 month:04 pages:419-445 extent:27 https://doi.org/10.1016/j.ejmech.2018.03.015 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 42.00 Biologie: Allgemeines VZ AR 150 2018 25 0425 419-445 27 |
| allfields_unstemmed |
10.1016/j.ejmech.2018.03.015 doi GBV00000000000550.pica (DE-627)ELV042585953 (ELSEVIER)S0223-5234(18)30250-2 DE-627 ger DE-627 rakwb eng 570 540 VZ BIODIV DE-30 fid 42.00 bkl Pal, Mousumi verfasserin aut Detailed account on activation mechanisms of ruthenium coordination complexes and their role as antineoplastic agents 2018transfer abstract 27 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Ruthenium (Ru) complexes are known for their promising anticancer activity presumably due to octahedral coordination geometry, slow ligand exchange rate, the range of different oxidation states and target specificity. This review article summarizes the physicochemical processes which are responsible for the selectivity of Ru complexes toward cancer cells over the normal cells. Emphasis has been given on the activation mechanism of Ru(III) complex administered as a prodrug and then the release of active species in an acidic environment of cancer cell through normal or photo induced hydrolysis or ligand oxidation. This article also elaborates how active Ru complex can be designed by their rate of hydrolysis, kinetics of ligand exchange, pKa of the aquated species. The article further articulates how Ru complexes inhibit tumor growth via multiple events such as transferrin/albumin binding, ROS generation, inhibition of glutathione-S-transferases and kinases and DNA intercalation. Based on the above understanding, examples of various Ru complexes with their in-vitro cell based cytotoxicity and mechanism of action have been described to make this review comprehensive for future Ru based anticancer drug development. In the end, comments have been made on some emerging concepts regarding lack of innertness of Ru(III) complexes vis-à-vis Ru(II) species. Ruthenium (Ru) complexes are known for their promising anticancer activity presumably due to octahedral coordination geometry, slow ligand exchange rate, the range of different oxidation states and target specificity. This review article summarizes the physicochemical processes which are responsible for the selectivity of Ru complexes toward cancer cells over the normal cells. Emphasis has been given on the activation mechanism of Ru(III) complex administered as a prodrug and then the release of active species in an acidic environment of cancer cell through normal or photo induced hydrolysis or ligand oxidation. This article also elaborates how active Ru complex can be designed by their rate of hydrolysis, kinetics of ligand exchange, pKa of the aquated species. The article further articulates how Ru complexes inhibit tumor growth via multiple events such as transferrin/albumin binding, ROS generation, inhibition of glutathione-S-transferases and kinases and DNA intercalation. Based on the above understanding, examples of various Ru complexes with their in-vitro cell based cytotoxicity and mechanism of action have been described to make this review comprehensive for future Ru based anticancer drug development. In the end, comments have been made on some emerging concepts regarding lack of innertness of Ru(III) complexes vis-à-vis Ru(II) species. Ligand exchange rate Elsevier Ruthenium-glutathione-S-transferase inhibitors Elsevier DNA damage Elsevier Anticancer Elsevier Ruthenium-coordination complex Elsevier Kinase inhibitor Elsevier Nandi, Utpal oth Mukherjee, Debaraj oth Enthalten in Elsevier Science Jose, Ajay ELSEVIER Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles 2018 Amsterdam [u.a.] (DE-627)ELV000457477 volume:150 year:2018 day:25 month:04 pages:419-445 extent:27 https://doi.org/10.1016/j.ejmech.2018.03.015 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 42.00 Biologie: Allgemeines VZ AR 150 2018 25 0425 419-445 27 |
| allfieldsGer |
10.1016/j.ejmech.2018.03.015 doi GBV00000000000550.pica (DE-627)ELV042585953 (ELSEVIER)S0223-5234(18)30250-2 DE-627 ger DE-627 rakwb eng 570 540 VZ BIODIV DE-30 fid 42.00 bkl Pal, Mousumi verfasserin aut Detailed account on activation mechanisms of ruthenium coordination complexes and their role as antineoplastic agents 2018transfer abstract 27 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Ruthenium (Ru) complexes are known for their promising anticancer activity presumably due to octahedral coordination geometry, slow ligand exchange rate, the range of different oxidation states and target specificity. This review article summarizes the physicochemical processes which are responsible for the selectivity of Ru complexes toward cancer cells over the normal cells. Emphasis has been given on the activation mechanism of Ru(III) complex administered as a prodrug and then the release of active species in an acidic environment of cancer cell through normal or photo induced hydrolysis or ligand oxidation. This article also elaborates how active Ru complex can be designed by their rate of hydrolysis, kinetics of ligand exchange, pKa of the aquated species. The article further articulates how Ru complexes inhibit tumor growth via multiple events such as transferrin/albumin binding, ROS generation, inhibition of glutathione-S-transferases and kinases and DNA intercalation. Based on the above understanding, examples of various Ru complexes with their in-vitro cell based cytotoxicity and mechanism of action have been described to make this review comprehensive for future Ru based anticancer drug development. In the end, comments have been made on some emerging concepts regarding lack of innertness of Ru(III) complexes vis-à-vis Ru(II) species. Ruthenium (Ru) complexes are known for their promising anticancer activity presumably due to octahedral coordination geometry, slow ligand exchange rate, the range of different oxidation states and target specificity. This review article summarizes the physicochemical processes which are responsible for the selectivity of Ru complexes toward cancer cells over the normal cells. Emphasis has been given on the activation mechanism of Ru(III) complex administered as a prodrug and then the release of active species in an acidic environment of cancer cell through normal or photo induced hydrolysis or ligand oxidation. This article also elaborates how active Ru complex can be designed by their rate of hydrolysis, kinetics of ligand exchange, pKa of the aquated species. The article further articulates how Ru complexes inhibit tumor growth via multiple events such as transferrin/albumin binding, ROS generation, inhibition of glutathione-S-transferases and kinases and DNA intercalation. Based on the above understanding, examples of various Ru complexes with their in-vitro cell based cytotoxicity and mechanism of action have been described to make this review comprehensive for future Ru based anticancer drug development. In the end, comments have been made on some emerging concepts regarding lack of innertness of Ru(III) complexes vis-à-vis Ru(II) species. Ligand exchange rate Elsevier Ruthenium-glutathione-S-transferase inhibitors Elsevier DNA damage Elsevier Anticancer Elsevier Ruthenium-coordination complex Elsevier Kinase inhibitor Elsevier Nandi, Utpal oth Mukherjee, Debaraj oth Enthalten in Elsevier Science Jose, Ajay ELSEVIER Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles 2018 Amsterdam [u.a.] (DE-627)ELV000457477 volume:150 year:2018 day:25 month:04 pages:419-445 extent:27 https://doi.org/10.1016/j.ejmech.2018.03.015 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 42.00 Biologie: Allgemeines VZ AR 150 2018 25 0425 419-445 27 |
| allfieldsSound |
10.1016/j.ejmech.2018.03.015 doi GBV00000000000550.pica (DE-627)ELV042585953 (ELSEVIER)S0223-5234(18)30250-2 DE-627 ger DE-627 rakwb eng 570 540 VZ BIODIV DE-30 fid 42.00 bkl Pal, Mousumi verfasserin aut Detailed account on activation mechanisms of ruthenium coordination complexes and their role as antineoplastic agents 2018transfer abstract 27 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Ruthenium (Ru) complexes are known for their promising anticancer activity presumably due to octahedral coordination geometry, slow ligand exchange rate, the range of different oxidation states and target specificity. This review article summarizes the physicochemical processes which are responsible for the selectivity of Ru complexes toward cancer cells over the normal cells. Emphasis has been given on the activation mechanism of Ru(III) complex administered as a prodrug and then the release of active species in an acidic environment of cancer cell through normal or photo induced hydrolysis or ligand oxidation. This article also elaborates how active Ru complex can be designed by their rate of hydrolysis, kinetics of ligand exchange, pKa of the aquated species. The article further articulates how Ru complexes inhibit tumor growth via multiple events such as transferrin/albumin binding, ROS generation, inhibition of glutathione-S-transferases and kinases and DNA intercalation. Based on the above understanding, examples of various Ru complexes with their in-vitro cell based cytotoxicity and mechanism of action have been described to make this review comprehensive for future Ru based anticancer drug development. In the end, comments have been made on some emerging concepts regarding lack of innertness of Ru(III) complexes vis-à-vis Ru(II) species. Ruthenium (Ru) complexes are known for their promising anticancer activity presumably due to octahedral coordination geometry, slow ligand exchange rate, the range of different oxidation states and target specificity. This review article summarizes the physicochemical processes which are responsible for the selectivity of Ru complexes toward cancer cells over the normal cells. Emphasis has been given on the activation mechanism of Ru(III) complex administered as a prodrug and then the release of active species in an acidic environment of cancer cell through normal or photo induced hydrolysis or ligand oxidation. This article also elaborates how active Ru complex can be designed by their rate of hydrolysis, kinetics of ligand exchange, pKa of the aquated species. The article further articulates how Ru complexes inhibit tumor growth via multiple events such as transferrin/albumin binding, ROS generation, inhibition of glutathione-S-transferases and kinases and DNA intercalation. Based on the above understanding, examples of various Ru complexes with their in-vitro cell based cytotoxicity and mechanism of action have been described to make this review comprehensive for future Ru based anticancer drug development. In the end, comments have been made on some emerging concepts regarding lack of innertness of Ru(III) complexes vis-à-vis Ru(II) species. Ligand exchange rate Elsevier Ruthenium-glutathione-S-transferase inhibitors Elsevier DNA damage Elsevier Anticancer Elsevier Ruthenium-coordination complex Elsevier Kinase inhibitor Elsevier Nandi, Utpal oth Mukherjee, Debaraj oth Enthalten in Elsevier Science Jose, Ajay ELSEVIER Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles 2018 Amsterdam [u.a.] (DE-627)ELV000457477 volume:150 year:2018 day:25 month:04 pages:419-445 extent:27 https://doi.org/10.1016/j.ejmech.2018.03.015 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 42.00 Biologie: Allgemeines VZ AR 150 2018 25 0425 419-445 27 |
| language |
English |
| source |
Enthalten in Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles Amsterdam [u.a.] volume:150 year:2018 day:25 month:04 pages:419-445 extent:27 |
| sourceStr |
Enthalten in Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles Amsterdam [u.a.] volume:150 year:2018 day:25 month:04 pages:419-445 extent:27 |
| format_phy_str_mv |
Article |
| bklname |
Biologie: Allgemeines |
| institution |
findex.gbv.de |
| topic_facet |
Ligand exchange rate Ruthenium-glutathione-S-transferase inhibitors DNA damage Anticancer Ruthenium-coordination complex Kinase inhibitor |
| dewey-raw |
570 |
| isfreeaccess_bool |
false |
| container_title |
Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles |
| authorswithroles_txt_mv |
Pal, Mousumi @@aut@@ Nandi, Utpal @@oth@@ Mukherjee, Debaraj @@oth@@ |
| publishDateDaySort_date |
2018-01-25T00:00:00Z |
| hierarchy_top_id |
ELV000457477 |
| dewey-sort |
3570 |
| id |
ELV042585953 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV042585953</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626001819.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ejmech.2018.03.015</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000550.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV042585953</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0223-5234(18)30250-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Pal, Mousumi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Detailed account on activation mechanisms of ruthenium coordination complexes and their role as antineoplastic agents</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">27</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Ruthenium (Ru) complexes are known for their promising anticancer activity presumably due to octahedral coordination geometry, slow ligand exchange rate, the range of different oxidation states and target specificity. This review article summarizes the physicochemical processes which are responsible for the selectivity of Ru complexes toward cancer cells over the normal cells. Emphasis has been given on the activation mechanism of Ru(III) complex administered as a prodrug and then the release of active species in an acidic environment of cancer cell through normal or photo induced hydrolysis or ligand oxidation. This article also elaborates how active Ru complex can be designed by their rate of hydrolysis, kinetics of ligand exchange, pKa of the aquated species. The article further articulates how Ru complexes inhibit tumor growth via multiple events such as transferrin/albumin binding, ROS generation, inhibition of glutathione-S-transferases and kinases and DNA intercalation. Based on the above understanding, examples of various Ru complexes with their in-vitro cell based cytotoxicity and mechanism of action have been described to make this review comprehensive for future Ru based anticancer drug development. In the end, comments have been made on some emerging concepts regarding lack of innertness of Ru(III) complexes vis-à-vis Ru(II) species.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Ruthenium (Ru) complexes are known for their promising anticancer activity presumably due to octahedral coordination geometry, slow ligand exchange rate, the range of different oxidation states and target specificity. This review article summarizes the physicochemical processes which are responsible for the selectivity of Ru complexes toward cancer cells over the normal cells. Emphasis has been given on the activation mechanism of Ru(III) complex administered as a prodrug and then the release of active species in an acidic environment of cancer cell through normal or photo induced hydrolysis or ligand oxidation. This article also elaborates how active Ru complex can be designed by their rate of hydrolysis, kinetics of ligand exchange, pKa of the aquated species. The article further articulates how Ru complexes inhibit tumor growth via multiple events such as transferrin/albumin binding, ROS generation, inhibition of glutathione-S-transferases and kinases and DNA intercalation. Based on the above understanding, examples of various Ru complexes with their in-vitro cell based cytotoxicity and mechanism of action have been described to make this review comprehensive for future Ru based anticancer drug development. In the end, comments have been made on some emerging concepts regarding lack of innertness of Ru(III) complexes vis-à-vis Ru(II) species.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ligand exchange rate</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ruthenium-glutathione-S-transferase inhibitors</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">DNA damage</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Anticancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ruthenium-coordination complex</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Kinase inhibitor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nandi, Utpal</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mukherjee, Debaraj</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Jose, Ajay ELSEVIER</subfield><subfield code="t">Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles</subfield><subfield code="d">2018</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000457477</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:150</subfield><subfield code="g">year:2018</subfield><subfield code="g">day:25</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:419-445</subfield><subfield code="g">extent:27</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ejmech.2018.03.015</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.00</subfield><subfield code="j">Biologie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">150</subfield><subfield code="j">2018</subfield><subfield code="b">25</subfield><subfield code="c">0425</subfield><subfield code="h">419-445</subfield><subfield code="g">27</subfield></datafield></record></collection>
|
| author |
Pal, Mousumi |
| spellingShingle |
Pal, Mousumi ddc 570 fid BIODIV bkl 42.00 Elsevier Ligand exchange rate Elsevier Ruthenium-glutathione-S-transferase inhibitors Elsevier DNA damage Elsevier Anticancer Elsevier Ruthenium-coordination complex Elsevier Kinase inhibitor Detailed account on activation mechanisms of ruthenium coordination complexes and their role as antineoplastic agents |
| authorStr |
Pal, Mousumi |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000457477 |
| format |
electronic Article |
| dewey-ones |
570 - Life sciences; biology 540 - Chemistry & allied sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
570 540 VZ BIODIV DE-30 fid 42.00 bkl Detailed account on activation mechanisms of ruthenium coordination complexes and their role as antineoplastic agents Ligand exchange rate Elsevier Ruthenium-glutathione-S-transferase inhibitors Elsevier DNA damage Elsevier Anticancer Elsevier Ruthenium-coordination complex Elsevier Kinase inhibitor Elsevier |
| topic |
ddc 570 fid BIODIV bkl 42.00 Elsevier Ligand exchange rate Elsevier Ruthenium-glutathione-S-transferase inhibitors Elsevier DNA damage Elsevier Anticancer Elsevier Ruthenium-coordination complex Elsevier Kinase inhibitor |
| topic_unstemmed |
ddc 570 fid BIODIV bkl 42.00 Elsevier Ligand exchange rate Elsevier Ruthenium-glutathione-S-transferase inhibitors Elsevier DNA damage Elsevier Anticancer Elsevier Ruthenium-coordination complex Elsevier Kinase inhibitor |
| topic_browse |
ddc 570 fid BIODIV bkl 42.00 Elsevier Ligand exchange rate Elsevier Ruthenium-glutathione-S-transferase inhibitors Elsevier DNA damage Elsevier Anticancer Elsevier Ruthenium-coordination complex Elsevier Kinase inhibitor |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
u n un d m dm |
| hierarchy_parent_title |
Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles |
| hierarchy_parent_id |
ELV000457477 |
| dewey-tens |
570 - Life sciences; biology 540 - Chemistry |
| hierarchy_top_title |
Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000457477 |
| title |
Detailed account on activation mechanisms of ruthenium coordination complexes and their role as antineoplastic agents |
| ctrlnum |
(DE-627)ELV042585953 (ELSEVIER)S0223-5234(18)30250-2 |
| title_full |
Detailed account on activation mechanisms of ruthenium coordination complexes and their role as antineoplastic agents |
| author_sort |
Pal, Mousumi |
| journal |
Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles |
| journalStr |
Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
zzz |
| container_start_page |
419 |
| author_browse |
Pal, Mousumi |
| container_volume |
150 |
| physical |
27 |
| class |
570 540 VZ BIODIV DE-30 fid 42.00 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Pal, Mousumi |
| doi_str_mv |
10.1016/j.ejmech.2018.03.015 |
| dewey-full |
570 540 |
| title_sort |
detailed account on activation mechanisms of ruthenium coordination complexes and their role as antineoplastic agents |
| title_auth |
Detailed account on activation mechanisms of ruthenium coordination complexes and their role as antineoplastic agents |
| abstract |
Ruthenium (Ru) complexes are known for their promising anticancer activity presumably due to octahedral coordination geometry, slow ligand exchange rate, the range of different oxidation states and target specificity. This review article summarizes the physicochemical processes which are responsible for the selectivity of Ru complexes toward cancer cells over the normal cells. Emphasis has been given on the activation mechanism of Ru(III) complex administered as a prodrug and then the release of active species in an acidic environment of cancer cell through normal or photo induced hydrolysis or ligand oxidation. This article also elaborates how active Ru complex can be designed by their rate of hydrolysis, kinetics of ligand exchange, pKa of the aquated species. The article further articulates how Ru complexes inhibit tumor growth via multiple events such as transferrin/albumin binding, ROS generation, inhibition of glutathione-S-transferases and kinases and DNA intercalation. Based on the above understanding, examples of various Ru complexes with their in-vitro cell based cytotoxicity and mechanism of action have been described to make this review comprehensive for future Ru based anticancer drug development. In the end, comments have been made on some emerging concepts regarding lack of innertness of Ru(III) complexes vis-à-vis Ru(II) species. |
| abstractGer |
Ruthenium (Ru) complexes are known for their promising anticancer activity presumably due to octahedral coordination geometry, slow ligand exchange rate, the range of different oxidation states and target specificity. This review article summarizes the physicochemical processes which are responsible for the selectivity of Ru complexes toward cancer cells over the normal cells. Emphasis has been given on the activation mechanism of Ru(III) complex administered as a prodrug and then the release of active species in an acidic environment of cancer cell through normal or photo induced hydrolysis or ligand oxidation. This article also elaborates how active Ru complex can be designed by their rate of hydrolysis, kinetics of ligand exchange, pKa of the aquated species. The article further articulates how Ru complexes inhibit tumor growth via multiple events such as transferrin/albumin binding, ROS generation, inhibition of glutathione-S-transferases and kinases and DNA intercalation. Based on the above understanding, examples of various Ru complexes with their in-vitro cell based cytotoxicity and mechanism of action have been described to make this review comprehensive for future Ru based anticancer drug development. In the end, comments have been made on some emerging concepts regarding lack of innertness of Ru(III) complexes vis-à-vis Ru(II) species. |
| abstract_unstemmed |
Ruthenium (Ru) complexes are known for their promising anticancer activity presumably due to octahedral coordination geometry, slow ligand exchange rate, the range of different oxidation states and target specificity. This review article summarizes the physicochemical processes which are responsible for the selectivity of Ru complexes toward cancer cells over the normal cells. Emphasis has been given on the activation mechanism of Ru(III) complex administered as a prodrug and then the release of active species in an acidic environment of cancer cell through normal or photo induced hydrolysis or ligand oxidation. This article also elaborates how active Ru complex can be designed by their rate of hydrolysis, kinetics of ligand exchange, pKa of the aquated species. The article further articulates how Ru complexes inhibit tumor growth via multiple events such as transferrin/albumin binding, ROS generation, inhibition of glutathione-S-transferases and kinases and DNA intercalation. Based on the above understanding, examples of various Ru complexes with their in-vitro cell based cytotoxicity and mechanism of action have been described to make this review comprehensive for future Ru based anticancer drug development. In the end, comments have been made on some emerging concepts regarding lack of innertness of Ru(III) complexes vis-à-vis Ru(II) species. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA |
| title_short |
Detailed account on activation mechanisms of ruthenium coordination complexes and their role as antineoplastic agents |
| url |
https://doi.org/10.1016/j.ejmech.2018.03.015 |
| remote_bool |
true |
| author2 |
Nandi, Utpal Mukherjee, Debaraj |
| author2Str |
Nandi, Utpal Mukherjee, Debaraj |
| ppnlink |
ELV000457477 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| doi_str |
10.1016/j.ejmech.2018.03.015 |
| up_date |
2024-07-06T16:34:24.595Z |
| _version_ |
1803848163890561024 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV042585953</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626001819.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ejmech.2018.03.015</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000550.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV042585953</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0223-5234(18)30250-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Pal, Mousumi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Detailed account on activation mechanisms of ruthenium coordination complexes and their role as antineoplastic agents</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">27</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Ruthenium (Ru) complexes are known for their promising anticancer activity presumably due to octahedral coordination geometry, slow ligand exchange rate, the range of different oxidation states and target specificity. This review article summarizes the physicochemical processes which are responsible for the selectivity of Ru complexes toward cancer cells over the normal cells. Emphasis has been given on the activation mechanism of Ru(III) complex administered as a prodrug and then the release of active species in an acidic environment of cancer cell through normal or photo induced hydrolysis or ligand oxidation. This article also elaborates how active Ru complex can be designed by their rate of hydrolysis, kinetics of ligand exchange, pKa of the aquated species. The article further articulates how Ru complexes inhibit tumor growth via multiple events such as transferrin/albumin binding, ROS generation, inhibition of glutathione-S-transferases and kinases and DNA intercalation. Based on the above understanding, examples of various Ru complexes with their in-vitro cell based cytotoxicity and mechanism of action have been described to make this review comprehensive for future Ru based anticancer drug development. In the end, comments have been made on some emerging concepts regarding lack of innertness of Ru(III) complexes vis-à-vis Ru(II) species.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Ruthenium (Ru) complexes are known for their promising anticancer activity presumably due to octahedral coordination geometry, slow ligand exchange rate, the range of different oxidation states and target specificity. This review article summarizes the physicochemical processes which are responsible for the selectivity of Ru complexes toward cancer cells over the normal cells. Emphasis has been given on the activation mechanism of Ru(III) complex administered as a prodrug and then the release of active species in an acidic environment of cancer cell through normal or photo induced hydrolysis or ligand oxidation. This article also elaborates how active Ru complex can be designed by their rate of hydrolysis, kinetics of ligand exchange, pKa of the aquated species. The article further articulates how Ru complexes inhibit tumor growth via multiple events such as transferrin/albumin binding, ROS generation, inhibition of glutathione-S-transferases and kinases and DNA intercalation. Based on the above understanding, examples of various Ru complexes with their in-vitro cell based cytotoxicity and mechanism of action have been described to make this review comprehensive for future Ru based anticancer drug development. In the end, comments have been made on some emerging concepts regarding lack of innertness of Ru(III) complexes vis-à-vis Ru(II) species.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ligand exchange rate</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ruthenium-glutathione-S-transferase inhibitors</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">DNA damage</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Anticancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ruthenium-coordination complex</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Kinase inhibitor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nandi, Utpal</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mukherjee, Debaraj</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Jose, Ajay ELSEVIER</subfield><subfield code="t">Electrochemical synthesis, photodegradation and antibacterial properties of PEG capped zinc oxide nanoparticles</subfield><subfield code="d">2018</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000457477</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:150</subfield><subfield code="g">year:2018</subfield><subfield code="g">day:25</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:419-445</subfield><subfield code="g">extent:27</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ejmech.2018.03.015</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.00</subfield><subfield code="j">Biologie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">150</subfield><subfield code="j">2018</subfield><subfield code="b">25</subfield><subfield code="c">0425</subfield><subfield code="h">419-445</subfield><subfield code="g">27</subfield></datafield></record></collection>
|
| score |
7.402629 |